Professional
Added to YB: 2025-06-13
Pitch date: 2025-03-31
VCYT [neutral]
Veracyte, Inc.
+46.71%
current return
Author Info
No bio for this author
Company Info
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis.
Market Cap
$3.1B
Pitch Price
$29.67
Price Target
N/A
Dividend
N/A
EV/EBITDA
32.57
P/E
103.44
EV/Sales
5.62
Sector
Biotechnology
Category
growth
Meridian Small-Cap Growth Fund Added On Portfolio Holding: Veracyte, Inc.
VCYT (holding update - added to position): Diagnostics co aiding clinicians w/ cancer decisions. Afirma & Decipher tests driving revenue growth & profitability. Stock declined on news of possible discontinuation of French subsidiary ($20M annual loss). Added to position as revenue loss & pipeline delays manageable given improved profitability & focus.
Read full article (1 min)